MYH14 and heart failure: In the Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure trial, patients with HFrEF were administered the drug omecamtiv mecarbil, which binds to the myosin filaments, increasing the myosin–actin-binding capacity and, thus, the contractile force of each power stroke.